4
Changes in Ownership
Spyre Therapeutics, Inc. Filed Acc 0001209191-22-047656
Options or other derivatives
- Interim CEO & General Counsel acquired 130,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Kastenmayer James Paul Interim CEO & General Counsel | 2022-08-23 | Grant or award · Employee Stock Option (right to buy) | +130,000 | 130,000 | D | ||
Loading xslF345X03/doc4.xml…